Latest News and Press Releases

New individual patient response data showed nearly all individuals (95%) treated with ZORYVE® (roflumilast) cream 0.3% had a measurable improvement in PASI

Arcutis today announced the FDA has approved an sNDA to expand the indication of ZORYVE (roflumilast) cream 0.3%.

The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with ZORYVEZORYVE is a once-daily, steroid-free cream for individuals with plaque psoriasis 12 years and above...

Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of...

Coverage at CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States was effective July 5All three of the largest pharmacy benefit managers in the United States have now included...

Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarterContinued expansion of commercial...

First novel steroid-free topical with a new mechanism of action approved for plaque psoriasis in over 25 yearsFirst ZORYVE approval outside of the U.S. marks key milestone for Arcutis WESTLAKE...

Eight additional national and regional health plans are now covering ZORYVE for plaque psoriasisZORYVE is a once-daily, steroid-free cream approved for use in both adults and adolescents with plaque...

Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growthSecured expanded commercial...

During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or...